Precigen

GenVec, Inc. (NASDAQ: GNVC) GenVec, Inc. is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec’s development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, influenza, malaria, and human immunodeficiency virus (HIV). In the area of animal health we are developing vaccines against foot-and-mouth disease (FMD).

EnviroFlight, LLC is a company based in Maysville, Kentucky, that specializes in producing sustainable animal and plant nutrition products by utilizing black soldier fly larvae to process waste materials, such as distillers grains and co-products from breweries and food production. Founded in 2009, the company offers a range of products including EnviroBug, EnviroMeal, EnviroOil, and EnviroFrass, which are designed for use in poultry, aquaculture, pets, and zoo animals, as well as serving as fertilizers. EnviroFlight aims to promote transformative change in the global food supply by developing nutrient sources that are socially responsible, free of toxins and antibiotics, and environmentally sustainable, thereby addressing the financial and ecological costs associated with traditional food production methods. EnviroFlight operates as a subsidiary of Darling Ingredients Inc.

Oxitec Limited is a biotechnology company based in Oxford, United Kingdom, focused on developing innovative solutions for controlling insect pests that transmit diseases and damage crops. Founded in 2002, the company employs proprietary genetic technology to enhance the effectiveness and safety of pest control methods, particularly the Sterile Insect Technique (SIT). Oxitec's products include various genetically modified strains of insects, such as the Aedes aegypti mosquito and the Diamondback moth, designed to reduce populations of disease-carrying and crop-damaging species. These strains are engineered for specific environments in Asia and Latin America and include features like female lethality and fluorescent markers for easy identification. With a mosquito production facility in Brazil, Oxitec aims to provide sustainable, non-toxic alternatives for pest management, thereby contributing to global health and agricultural productivity while minimizing environmental impact.

ActoGeniX is a biopharmaceutical company established in 2006 and headquartered in Zwijnaarde, Belgium. It focuses on the development and commercialization of a new generation of biological drugs utilizing a proprietary technology platform. This platform employs living non-pathogenic microorganisms for the oral delivery of biopharmaceuticals, addressing unmet needs in gastrointestinal, immunological, and metabolic diseases. Through its innovative approach, ActoGeniX aims to advance therapeutic options in these critical areas of healthcare.

Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. Our regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. Our first investigational product candidate, NeoCart®, leverages our platform to provide an innovative treatment in the orthopedic space, specifically cartilage damage in the knee.

Medistem, established in 2005, focuses on developing and commercializing adult stem cell-based therapies. The company has built a robust portfolio, including 16 families of patent applications and numerous scientific publications. It has also out-licensed certain technologies to generate revenue. Medistem's primary product is the Endometrial Regenerative Cell (ERC), a universal donor pluripotent stem cell. This innovative therapy is being developed for critical limb ischemia, an advanced form of peripheral artery disease. The ERC aims to promote new blood vessel formation, reduce inflammation, regulate immune system function, and enhance tissue repair and healing. Medistem operates on a fee-for-service basis, leveraging its expertise in adult stem cell applications.

Immunologix, Inc. develops and produces antibody-based therapeutics for various biological targets. It produces human monoclonal antibodies against viral, bacterial, and tumor antigens, as well as human auto antigens. The company was incorporated in 2008 and is based in Charleston, South Carolina.

Agarigen is a North Carolina-based company that has developed a novel, mushroom-based expression platform for the rapid, high yield production of recombinant proteins.